Technical Principles and Clinical Value of Fluorescence Quantitative PCR Hepatitis B Virus Nucleic Acid Detection Kits

I. Technical Principles and Core Advantages

The Hepatitis B Virus Nucleic Acid Detection Kit (Fluorescence Quantitative PCR Method) is based on real-time fluorescence quantitative polymerase chain reaction (qPCR) technology. By designing specific primers and fluorescently labeled probes, it monitors changes in fluorescence signals in real time during the amplification process to achieve quantitative detection of HBV DNA. Compared with traditional qualitative PCR or immunological marker detection, this method features high sensitivity, a wide linear range, and absolute quantification capability. The common lower limit of detection can reach 10 IU/mL, enabling effective identification of occult infections with low viral load. In addition, the fluorescence quantitative PCR method does not require post-amplification electrophoresis with tube opening, reducing the risk of aerosol contamination, and can monitor sample extraction and amplification efficiency through an internal standard system to ensure result reliability.

II. Key Points for Clinical Application

In clinical practice, the Hepatitis B Virus Nucleic Acid Detection Kit (Fluorescence Quantitative PCR Method) is mainly used in the following scenarios:

Early diagnosis and screening: For carriers who are HBsAg-positive but have normal liver function, quantitative detection of HBV DNA helps determine viral replication activity and decide whether antiviral treatment should be initiated.

Treatment monitoring: During treatment with nucleos(t)ide analogues or interferon, regular monitoring of viral load changes can evaluate efficacy and promptly identify virological breakthrough or drug-resistant mutations.

Drug resistance testing: Combined with sequence analysis, some kits can simultaneously detect common resistance sites (such as rtM204V/I, rtL180M, etc.), providing a basis for decisions on switching medications.

It should be noted that the test results of this kit are affected by sample type (serum or plasma), type of anticoagulant (EDTA is superior to heparin), storage conditions, and operating procedures. Clinicians should make a comprehensive judgment in combination with ALT, hepatitis B serological markers, and liver fibrosis indicators, and avoid making a diagnosis based solely on a single viral load value.

III. Quality Specifications and Performance Verification

According to the requirements of the National Medical Products Administration (NMPA), the Hepatitis B Virus Nucleic Acid Detection Kit (Fluorescence Quantitative PCR Method) must meet the performance indicators in the regulations for the registration and administration of in vitro diagnostic reagents, including accuracy, precision, minimum detection limit, linear range, interfering substances, and cross-reactivity. When introducing this kit, laboratories should carry out necessary performance verification, such as calibration using international standards (WHO International Units), to ensure comparability of results between different batches. In addition, it is recommended to regularly participate in national or provincial external quality assessment programs to maintain testing quality.